ROCKET PHARMACEUTICALS, INC. (RCKT): restructuring charge — Rocket Pharmaceuticals cuts workforce 30%, extends cash runway into Q2 2027

ROCKET PHARMACEUTICALS, INC.

Reduction in workforce of ~30%; expected to cut 12-month operating expenses by ~25%.
Estimated $3.5M in restructuring charges in H2 2025; severance for ~80 employees.
Board approved Plan on June 18, 2025; RIF began July 23, to be completed by August 8, 2025.
Restructuring aims to maximize near-term value and extend operational runway into Q2 2027.

item 2.05

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

ROCKET PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $3.5 million (approximately 30%).

Type: restructuring
Charge: approximately $3.5 million
Headcount: approximately 30%

Exact text from the filing

The Company began notifying affected employees on July 23, 2025, and expects the RIF to be completed by August 8, 2025. The Company estimates that it will incur approximately $3.5 million in restructuring and restructuring-related charges in the second half of 2025 in connection with the Plan, consisting primarily of employee severance payments and other

View on SEC.gov

Browse all restructurings & charges →

ROCKET PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-25-026946

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.